12:42 PM EDT, 03/12/2024 (MT Newswires) -- Cadrenal Therapeutics ( CVKD ) on Tuesday filed a registration statement for the potential sale of up to $100 million of its securities from time to time.

The filing covers the potential sale of common stock, preferred stock, debt securities, warrants and units.

Unless otherwise stated in a prospectus supplement, the company said it plans to use the net proceeds from the potential sale for working capital and general corporate purposes, which may include repurchase of securities.

Cadrenal shares were down 4.2% in recent trading on Tuesday.

Price: 0.59, Change: -0.03, Percent Change: -4.77